Search results
Results from the WOW.Com Content Network
UR-144 (Abbott patent) has been detected as an ingredient of synthetic cannabis smoking blends in New Zealand, and subsequently banned from sale as a temporary class drug on 6 April 2012. [7] It has also been encountered in smoking blends and subsequently banned in Russia. [8] As of October 2015 UR-144 is a controlled substance in China. [9]
5F-CUMYL-PINACA (also known as SGT-25 and sometimes sold in e-cigarette form as C-Liquid) [1] is an indazole-3-carboxamide based synthetic cannabinoid. [2] 5F-CUMYL-PINACA acts as a potent agonist for the cannabinoid receptors, with the original patent claiming approximately 4x selectivity for CB 1, having an EC 50 of <0.1 nM for human CB 1 receptors and 0.37 nM for human CB 2 receptors. [3]
XLR-11 (5"-fluoro-UR-144 or 5F-UR-144) is a drug that acts as a potent agonist for the cannabinoid receptors CB 1 and CB 2 with EC 50 values of 98 nM and 83 nM ...
EG-2201 is a synthetic cannabinoid belonging to the indole-3-carboxamide family. [1] It has been identified as a designer drug and is structurally related to other synthetic cannabinoids, such as EG-018 and MDMB-CHMCZCA.
NNE1 (also known as NNEI, MN-24 and AM-6527) is an indole-based synthetic cannabinoid, representing a molecular hybrid of APICA and JWH-018 [1] that is an agonist for the cannabinoid receptors, with K i values of 60.09 nM at CB 1 and 45.298 nM at CB 2 and EC 50 values of 9.481 nM at CB 1 and 1.008 nM at CB 2. [2]
Compared to THC, which is a partial agonist at CB 1 receptors, JWH-018, and many synthetic cannabinoids, are full agonists. JWH-018 may cause intense anxiety, agitation, and in rare cases, has been assumed to have been the cause of seizures and convulsions. JWH-018 and analogs of it may present serious dangers to the user when used to excess. [22]
AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole) is a recreational designer drug that acts as a potent but nonselective full agonist for the cannabinoid receptor. [3] It is part of the AM series of cannabinoids discovered by Alexandros Makriyannis at Northeastern University .
O-1602 is a synthetic compound most closely related to abnormal cannabidiol, and more distantly related in structure to cannabinoid drugs such as THC.O-1602 does not bind to the classical cannabinoid receptors CB 1 or CB 2 with any significant affinity, but instead is an agonist at several other receptors which appear to be related to the cannabinoid receptors, particularly GPR18 and GPR55.